CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
We investigated the significance of surface antigen expression for prognosis by focusing on a specific subtype, AML with t(8;21). The investigation included 144 patients with AML with t(8;21) in the JALSG AML97 study. AML with t(8;21) expressed CD19 (36%), CD34 (96%), and CD56 (65%) more frequently than did other subtypes of AML. CD19 expression had a significant favorable effect on CR (95.7% vs. 83.8%; P=0.049). Univariate analysis showed that increased white blood cell (WBC) counts (WBC ≥ 20 × 10(9)/L), CD19 negativity, and CD56 positivity were critical adverse factors for relapse after CR; multivariate analysis revealed that WBC count and CD56 expression were independent adverse risk factors (HR 2.18; P=0.045, HR 2.30; P=0.011, respectively). We concluded that CD56 expression has a possible role in risk stratification for patients with AML with t(8;21).